BALTIC STATES PHARMA MARKET OVERVIEW · •Introduction •General overview • Sales dynamics in...

BALTIC STATES PHARMA MARKET OVERVIEW

Secondary sales analysis

Content

• Introduction

• General overview• Sales dynamics in Baltic states 2009 – 2014• Generic / Originator drugs market share in Baltic states 2013 1Q-3Q• Rx and OTC dispensing types drugs market

in Baltic states, Lithuania, Latvia and Estonia 2009 - 2014• Hospitals and pharmacies segments market share• Hospital segment Generic/ Originator medicine market share• Pharmacy segment Generic/ Originator medicine market share

• TOP 10 Producers• Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q• Latvian pharmacy and hospital market 2012 1Q – 2013 3Q• Estonian pharmacy and hospital market 2012 1Q – 2013 2Q

• TOP 5 ATC3 categories• Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q• Latvian pharmacy and hospital market 2012 1Q – 2013 3Q• Estonian pharmacy and hospital market 2012 1Q – 2013 2Q

2

Meaning of abbreviation

Volume – measure of sales quantity;

Value – wholesales amount in Euros;

CAGR – Compound Annual Growth Rate refers to the year-over-year average growth rate of an measured event over a specified period of time;

YoY – Year-over-year comparison method of evaluating two or more measured events to compare the results at one time period with those from another time period (or series of time periods), on an annualized basis;

YTD – year to date refers to measured event characteristics in time period beginning of January 1st to today’s date or specified date;

MS – market share.

3

Introduction

The following analysis are based on Lithuania, Latvia and Estonia pharmaceutical market secondary sales (wholesales) data collected by PharmaZOOM project developed by SoftDent.

Analysis period includes:

• 2009 – 2013 3Q in Latvia and Lithuania

• 2009 – 2013 2Q in Estonia

Type of medicines are restricted to OTC and Rx (Food supplements and medicine supplies are not included).

4

General overview

Source: PharmaZOOM;Period: LT, LV 2009 1Q – 2013 3Q; EE 2009 1Q–2013 2Q;

5

LT

LV

EE

Estimate

Growth

Sales dynamics in Baltic states 2009 – 2014

74 mln 72 mln 71 mln 70 mln

54 mln

19 mln

75 mln

45 mln 45 mln 43 mln 43 mln 34 mln

12 mln

47 mln

24 mln 24 mln 25 mln 26 mln 14 mln

14 mln28 mln

396 mln EUR

387 mln EUR

399 mln EUR

415 mln EUR 324 mln

EUR

121 mln EUR

466 mln EUR

233 mln EUR

236 mln EUR

236 mln EUR

242 mln EUR

186 mln EUR

65 mln EUR

258 mln EUR

182 mln EUR

186 mln EUR

198 mln EUR

219 mln EUR

115 mln EUR

115 mln EUR

244 mln EUR

0

100

200

300

400

500

600

700

800

900

1000

0

20

40

60

80

100

120

140

160

2009 2010 2011 2012 2013 2014 2009 2010 2011 2012 2013 2014

Volume Value

5,29%

1,67%2,97%

4,16%

7,22%4,75%

1,15%

6,38%

2,85%0,93% 0,11%

2,71%

3,61%

2,61%3,65%5,58%

3,86% 3,68% 2,50%

6,22%

10,85%

4,87%6,24%

-2,91%-1,07% -1,90% -2,16%

-0,24%

-4,82%

General overview

2,19% 6,10% 4,12% 0,20% 0,89% 0,83% 1,40% 0,69% 0,17%0,01% 0,49% 0,08% 1,09% 0,45% 0,98% 0,15% 0,49% 1,04% 3,66% 3,82% 5,81% 1,55% 0,45% 2,65%

-0,04% -1,80% -0,15% -1,87% -1,58% -1,73% -0,42% -1,73% -1,89% -2,42% -3,02% -2,90% -1,09% -0,33% -2,19%-0,74% -1,62% -1,43% -0,24% -1,63% -0,99% -2,64% -0,95% -0,34%

6

Originator

Generic

Originator market share growth YoY

Generic / Originator drugs market sharein Baltic states 2013 1Q-3Q


25% 25% 26% 27% 27%

60% 59% 58% 58% 58%

21% 21% 22% 22% 21%

56% 54% 54% 55% 54%

37% 37% 36% 35% 35%

67% 65% 65% 66% 66%

75% 75% 74% 73% 73%

40% 41% 42% 42% 42%

79% 79% 78% 78% 79%

44% 46% 46% 45% 46%

63% 63% 64% 65% 65%

33% 35% 35% 34% 34%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE LT LV EE

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013

Volume Value

Generic market share growth YoY

General overview

7

Rx and OTC dispensing types drugs marketin Baltic states 2009 - 2014


665 mln EUR 666 mln EUR 685 mln EUR726 mln EUR

512 mln EUR

247 mln EUR

790 mln EUR

146 mln EUR 143 mln EUR147 mln EUR

150 mln EUR 114 mln EUR

54 mln EUR178 mln EUR

0

100

200

300

400

500

600

700

800

900

1.000

2009 2010 2011 2012 2013 2014

VA

LUE

mln

EUR

Rx Rx OTC OTC Trend Rx Trend OTC

0,10%2,95%

5,97%4,45% 4,17%

2,57% 2,37%

11,48%

6,50%

-1,72%

General overview

8

330 mln EUR 323 mln EUR 330 mln EUR 345 mln EUR

268 mln EUR

100 mln EUR

384 mln EUR




0

50

100

150

200

250

300

350

400

450

500

2009 2010 2011 2012 2013 2014

VA

LUE,

mln

EUR


Rx and OTC dispensing types drugs marketin Lithuania 2009 - 2014


2,19%

4,46%6,51%

4,38%

6,89%

2,70%

10,68%6,55%

-2,06%-2,64%

General overview

9

Rx and OTC dispensing types drugs marketin Latvia 2009 - 2014


179 mln EUR 181 mln EUR 184 mln EUR 191 mln EUR

144 mln EUR

49 mln EUR

197 mln EUR

54 mln EUR 54 mln EUR 52 mln EUR52 mln EUR 42 mln EUR

16 mln EUR

61 mln EUR

0

50

100

150

200

250

300

2009 2010 2011 2012 2013 2014

VA

LUE,

mln

EUR


1,37% 1,22%

3,78%1,45% 2,00%

11,84%

5,14%

-0,52%

-3,60%

-1,06%

General overview

10

Rx and OTC dispensing types drugs marketin Estonia 2009 - 2014



191 mln EUR

100 mln EUR

98 mln EUR

210 mln EUR


26 mln EUR

29 mln EUR 16 mln EUR


0

50

100

150

200

250

2009 2010 2011 2012 2013 2014

VA

LUE,

mln

EUR


3,22%

6,43%

11,25%

3,72%5,88%4,89%

8,27%12,81% 8,85%

-1,89%

General overview

11

Hospitals and pharmacies segmentsmarket share

20% 21% 26% 28% 28%

6% 7% 6% 6% 5% 8% 9% 11% 9% 7%

80% 79% 74% 72% 72%

94% 93% 94% 94% 95% 92% 91% 89% 91% 93%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Mar

ket

shar

e b

y

VA

LUE

8% 9% 10% 10% 9% 4% 4% 4% 5% 5% 9% 8% 7% 5% 5%

92% 91% 90% 90% 91% 96% 96% 96% 95% 95% 91% 92% 93% 95% 95%

0%

20%

40%

60%

80%

100%

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013

Estonia Latvia Lithuania

Mar

ket

shar

e b

y

VO

LUM

E

HospitalPharmacies

182 186 198 219115

233 236 236 242 186

396 387 399 415324118

62

111

0

100

200

300

400

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013


Tota

l sal

es

VA

LUE

mln

EUR


General overview

76% 74% 77% 80% 79%66% 66% 63% 56% 53%

69% 70% 72% 66% 61%

24% 26% 23% 20% 21%34% 34% 37% 44% 47%

31% 30% 28% 34% 39%

0%

20%

40%

60%

80%

100%

Mar

ket

shar

e b

y

VA

LUE

12

Hospital segment Generic/Originator medicine market share

36 4051

62

33

15 16 15 14 9

32 3445

3823

33

6

17

0

10

20

30

40

50

60

70

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013


Ho

spit

al s

ales

VA

LUE

mln

EUR

39% 41% 47% 44% 41%24% 27% 24%

17% 13% 11% 12% 14% 18% 19%

61% 59% 53% 56% 59%76% 73% 76%

83% 87% 89% 88% 86% 82% 81%

0%

20%

40%

60%

80%

100%

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013


Mar

ket

shar

e b

y

VO

LUM

E

Originator

Generic


General overview

64% 62% 61% 61% 61% 55% 53% 54% 55% 54% 59% 58% 56% 57% 58%

36% 38% 39% 39% 39% 45% 47% 46% 45% 46% 41% 42% 44% 43% 42%

0%

20%

40%

60%

80%

100%

Mar

ket

shar

e b

y

VA

LUE

37% 36% 35% 35% 34%21% 21% 22% 22% 22% 27% 26% 27% 27% 27%

63% 64% 65% 65% 66%79% 79% 78% 78% 78% 73% 74% 73% 73% 73%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013


Mar

ket

shar

e b

y

VO

LUM

E

Originator

Generic

13

Pharmacy segment Generic/Originator medicine market share

145 146 147 15883

219 219 221 228177

364 353 353 377301

85

57

95

0

100

200

300

400

2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013

Ph

arm

acy

sale

s

VA

LUE

mln

EUR


TOP 10 corporations by sales value

HO

SPIT

AL

PR

OD

UC

ERS

Rank 2013 (2012) Corporation Sales, k € 2012Sales, k € 2013 1Q-3Q

Growth YoY2013 1Q-3Q CAGR 2010-2012

Market share (value) 2012


1 (4) Fresenius 2.542 1.966 5,71% 6,23% 7,37% 8,64%

2 (1) Valeant 3.852 1.846 -43,58% 65,37% 12,96% 8,11%

3 (6) Takeda 1.676 1.371 10,78% 21,81% 4,90% 6,02%

4 (10) Johnson & Johnson 1.340 1.208 1063,53% 12,59% 0,41% 5,31%

5 (3) Abbott 2.871 1.138 1,06% 11,26% 4,46% 5,00%

6 (8) GlaxoSmithKline 1.398 1.093 5,72% -2,31% 4,10% 4,80%

7 (12) Octapharma 1.224 1.086 15,69% 187,00% 3,72% 4,77%

8 (11) Sandoz 1.256 1.046 9,75% -12,32% 3,77% 4,59%

9 (5) Bayer 2.043 970 -40,28% 5,62% 6,43% 4,26%

10 (7) Genzyme 1.500 959 -18,28% -0,74% 4,65% 4,21%

TOP 1-10 19.702 12.683 -4,80% 17,69% 52,78% 55,70%

TOP 11-20 10.655 5.508 -15,67% 5,89% 25,87% 24,19%

Other 7.225 4.579 -15,03% -11,60% 21,35% 20,11%

Total 37.581 22.770 -9,79% 4,98% 100,00% 100,00%

PH

AR

MA

CY

PR

OD

UC

ERS 1 (1) Berlin Chemie 28.305 22.040 5,93% -2,20% 7,52% 7,32%

2 (2) Servier 24.488 18.854 3,16% 7,44% 6,60% 6,27%

3 (6) Pfizer 18.439 16.491 28,81% -1,17% 4,63% 5,48%

4 (5) GlaxoSmithKline 19.384 16.092 13,06% -6,37% 5,14% 5,35%

5 (3) Sanofi-Aventis 20.714 15.009 -3,13% -2,97% 5,60% 4,99%

6 (4) KRKA 20.583 14.174 -6,60% 11,73% 5,48% 4,71%

7 (10) Novartis 12.395 13.628 72,95% 23,83% 2,85% 4,53%

8 (9) Teva 14.475 11.893 12,29% -1,88% 3,83% 3,95%

9 (8) Sandoz 14.606 11.819 10,39% 6,30% 3,87% 3,93%

10 (7) AstraZeneca 14.656 11.243 4,30% 0,57% 3,90% 3,74%

TOP 1-10 188.044 151.242 10,60% -0,08% 49,42% 50,26%

TOP 11-20 84.667 69.459 10,92% 0,55% 22,63% 23,08%

Other 104.782 80.228 3,73% 4,33% 27,95% 26,66%

Total 377.493 300.928 8,76% 3,42% 100,00% 100,00%

14

Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q


HO

SPIT

AL

PR

OD

UC

ERS





1 (1) Takeda 1.856 1.437 8,99% -16,22% 12,13% 15,82%

2 (7) Fresenius Kabi 674 583 28,04% 64,94% 4,18% 6,41%

3 (2) Pfizer 1.132 578 -36,91% 0,10% 8,43% 6,36%

4 (4) Sanofi-Aventis 839 571 -14,05% -1,32% 6,11% 6,29%

5 (3) Teva 1.001 529 -29,52% 26,26% 6,90% 5,83%

6 (6) Sopharma 724 467 -11,86% 11,66% 4,87% 5,14%

7 (9) Abbott 547 442 6,94% -21,94% 3,80% 4,86%

8 (8) Medochemie 548 384 -3,26% -0,74% 3,65% 4,23%

9 (20) mn pharmaceuticals 227 275 63,03% 142,78% 1,55% 3,03%

10 (16) Boehringer Ingelheim 307 265 33,03% -9,79% 1,83% 2,91%

TOP 1-10 7.855 5.530 -4,85% 4,34% 53,46% 60,90%

TOP 11-20 2.925 2.018 -8,22% 8,89% 20,22% 22,22%

Other 3.472 1.534 -46,39% -14,77% 26,31% 16,89%

Total 14.252 9.081 -16,46% -6,57% 100,00% 100,00%

PH

AR

MA

CY

PR

OD

UC

ERS 1 (2) Servier 11.803 9.012 -0,16% 8,42% 5,34% 5,08%

2 (3) Sanofi-Aventis 11.484 8.865 3,68% -2,92% 5,06% 5,00%

3 (6) Novartis 9.814 8.115 11,66% 12,07% 4,30% 4,57%

4 (1) Pfizer 11.956 8.078 -12,09% -0,68% 5,43% 4,55%

5 (5) Teva 9.977 7.505 2,93% 6,22% 4,31% 4,23%

6 (8) Merck Sharp & Dohme 8.565 7.475 20,79% 6,33% 3,66% 4,21%

7 (4) Hoffmannn-La Roche 11.293 7.340 -16,91% 34,33% 5,23% 4,14%

8 (7) GlaxoSmithKline 9.745 7.237 -0,83% -6,05% 4,32% 4,08%

9 (9) Berlin Chemie 8.253 6.583 7,90% -8,84% 3,61% 3,71%

10 (10) KRKA 7.564 6.160 11,11% 7,02% 3,28% 3,47%

TOP 1-10 100.454 76.372 1,43% 1,62% 44,53% 43,05%

TOP 11-20 59.921 47.502 7,78% 3,26% 26,07% 26,78%

Other 67.636 53.514 7,66% -0,42% 29,40% 30,17%

Total 228.010 177.389 4,92% 1,97% 100,00% 100,00%

15


Latvian pharmacy and hospital market 2012 1Q – 2013 3Q



HO

SPIT

AL

PR

OD

UC

ERS





1 (1) Hoffmann-La Roche 11.577 6.128 3,41% 20,34% 18,95% 18,65%

2 (2) Abbott 5.344 2.922 5,16% 55,21% 8,89% 8,89%

3 (4) Johnson & Johnson UAB 4.002 2.528 19,96% 63,23% 6,74% 7,69%

4 (3) ViiV Healthcare UK Limited 4.549 1.628 -28,75% 2898,21% 7,31% 4,95%

5 (6) Pfizer 3.016 1.592 4,12% 1,47% 4,89% 4,84%

6 (5) Octapharma (IP) Limited 3.096 1.543 23,94% 38,27% 3,98% 4,70%

7 (7) GE Healthcare AS 2.478 1.365 8,46% 23,04% 4,02% 4,15%

8 (8) Merck Sharp & Dohme 2.154 1.032 0,85% 23,61% 3,27% 3,14%

9 (12) Baxter AG 1.374 970 47,80% -2,49% 2,10% 2,95%

10 (14) Genzyme Corp. 1.354 945 34,87% 28,87% 2,24% 2,87%

TOP 1-10 38.945 20.652 5,86% 27,19% 62,39% 62,85%

TOP 11-20 11.697 5.963 -5,55% 5,17% 20,19% 18,15%

Other 10.893 6.246 14,68% 13,79% 17,42% 19,01%

Total 61.535 32.861 5,09% 24,22% 100,00% 100,00%

PH

AR

MA

CY

PR

OD

UC

ERS 1 (1) AstraZeneca AB 9.720 5.204 7,83% -8,24% 6,13% 6,30%

2 (2) GlaxoSmithKline 9.449 5.171 11,06% 0,55% 5,91% 6,27%

3 (3) Sandoz d.d. 9.053 4.529 -0,99% 4,49% 5,81% 5,49%

4 (4) Teva 9.024 4.462 0,17% 11,45% 5,66% 5,41%

5 (7) Takeda 7.938 4.273 9,44% 5,53% 4,96% 5,18%

6 (5) Merck Sharp & Dohme 8.370 4.188 -1,45% -1,13% 5,39% 5,07%

7 (6) Novartis Pharma 8.144 4.142 -0,31% 8,34% 5,27% 5,02%

8 (8) Sanofi Aventis 7.828 3.997 3,49% -2,74% 4,90% 4,84%

9 (10) Berlin-Chemie AG (Menarini Group) 6.381 3.434 11,07% 2,79% 3,92% 4,16%

10 (11) Bayer 6.152 3.429 15,07% 10,78% 3,78% 4,15%

TOP 1-10 82.059 42.828 5,09% 1,11% 51,74% 51,89%

TOP 11-20 41.029 20.959 1,84% 4,24% 26,13% 25,39%

Other 34.783 18.746 7,50% 5,26% 22,14% 22,71%

Total 157.872 82.533 4,77% 3,82% 100,00% 100,00%

16

Estonian pharmacy and hospital market 2012 1Q – 2013 2Q


TOP 5 ATC3 categories

17

RANK 2013 (2012) ATCSales, k € 2013 1Q-3Q

Growth YoY 2013 1Q-3Q

Market share by value 2013 1Q-3Q Products TOP 3 Product Sales, k € 2013 1Q-3Q

Product Growth 2013 YoY 2013 1Q-3Q

HO

SPIT

AL

ATC

CA

TEG

OR

IES

1 (1) V08A 1916 -16,24% 8,42% Omnipaque 772 -12,96%

Ultravist 732 -37,85%

Visipaque 398 112,33%

2 (2) J05A 1517 -21,02% 6,66% Reyataz 668 -25,32%

Baraclude 91 -41,44%

Kaletra caps. 202 -45,05%

3 (3) B01A 1207 -11,81% 5,30% Clexane 104 -62,41%

Zibor 158 33,40%

Fraxiparine 551 16,99%

4 (7) J01D 1183 5,80% 5,20% Axetine 145 -22,49%

Reflin 127 -26,41%

Zepilen 196 18,34%

5 (5) B05X 1176 -4,88% 5,16% Natrio chloridas Fresenius 842 -0,52%

Sodium Chloride Braun 90 -42,44%

Magnio sulfatas Sanitas 114 7,55%

PH

AR

MA

CY

ATC

CA

TEG

OR

IES

1 (2) M01A 12867 12,93% 4,28% Arcoxia 948 71,45%

Nimesil 1580 13,46%

Ibumetin Nycomed 1163 17,97%

2 (1) L03A 11673 -2,36% 3,88% Pegasys 2056 15,39%

Copaxone 1703 -11,48%

Rebif 2505 -4,62%

3 (3) R03A 11250 2,06% 3,74% Symbicort 4644 6,95%

Seretide 4564 -2,62%

Berodual 595 -11,89%

4 (5) A10A 10412 4,89% 3,46% Lantus SoloStar 1820 14,46%

NovoMix 2725 -0,69%

Humalog Mix 2104 5,01%

5 (4) C09B 10307 1,43% 3,43% Presteram 2684 9,81%

Noliterax 1727 11,60%

Noliprel 1726 -11,28%

Lithuanian pharmacy and hospital market 2012 1Q – 2013 3Q



18





HO

SPIT

AL

ATC

CA

TEG

OR

IES

1 (3) V08A 1235 15,44% 12,59% Omnipaque 412 -10,03%

Visipaque 768 28,39%

Iopamigita 42 655,36%

2 (2) B01A 1033 -14,58% 10,53% Clexane 232 -26,28%

Fraxiparine 131 -15,84%

Fragmin 169 -29,74%

3 (1) G03A 727 -39,99% 7,41% Evra 196 -39,65%

Yarina 177 -40,78%

Yasminelle 354 -39,78%

4 (4) J01D 608 -6,09% 6,19% Axetine 170 -0,58%

Ceftriaxone-BCP 117 140,56%

Cefazolin-BCPP 79 -29,25%

5 (7) J01C 466 3,87% 4,75% Pamecil 57 0,03%

Tazocin 97 16,37%

Ampisid 275 63,03%

PH

AR

MA

CY

ATC

CA

TEG

OR

IES

1 (1) L03A 7709 5,18% 4,35% Neulasta 2032 1,23%

Rebif 44 1475 17,33%

Avonex 1219 0,24%

2 (2) M01A 7125 10,07% 4,02% Ibumetin 1749 11,67%

Nimesil 364 2,00%

Dicloberl 333 3,94%

3 (4) C09B 5987 0,29% 3,38% Presteram 1531 -7,96%

Noliprel Forte 692 2,33%

Noliterax 768 17,56%

4 (6) A10B 5835 15,22% 3,29% Janumet 1118 13,57%

Metforal 495 -11,97%

Competact 599 -27,20%

5 (5) A10A 5763 -2,82% 3,25% Novorapid 1111 0,90%

Novomix 763 -23,43%

Lantus 1137 24,02%

Latvian pharmacy and hospital market 2012 1Q – 2013 3Q



19





HO

SPIT

AL

ATC

CA

TEG

OR

IES

1 (1) L04A 1455 14,18% 13,49% Enbrel 952 5,12%

Orencia 42 161,54%

Simponi 425 37,77%

2 (2) V08A 1252 9,98% 11,61% Omnipaque 204 56,52%

Ultravist 142 -8,96%

Visipaque 907 6,51%

3 (5) J05A 689 48,33% 6,39% Norvir 134 17,29%

Prezista 503 53,65%

Ziagen 10 -3,20%

4 (6) L01X 570 40,77% 5,28% Avastin 319 4,19%

Iressa 92 219,27%

Topotecan Teva 47 64,28%

5 (7) B01A 389 -2,75% 3,61% Arixtra 16 -34,51%

Clexane 293 -3,45%

Zibor 34 -4,49%

PH

AR

MA

CY

ATC

CA

TEG

OR

IES

1 (1) A10A 4314 -1,41% 5,33% Levemir Flexpen 1127 -1,86%

Novorapid Flexpen 896 1,69%

Lantus Solostar 1301 0,89%

2 (2) M01A 3799 17,59% 4,69% Ibumetin 925 50,77%

Arcoxia 445 15,55%

Glucadol 271 -12,27%

3 (3) R03A 3261 11,40% 4,03% Seretide Diskus 1106 4,50%

Symbicort Turbuhaler 1258 19,38%

Seretide Inhaler 188 13,88%

4 (4) L03A 2897 2,46% 3,58% Pegasys 696 -6,67%

Rebif 44 Mcg 366 0,00%

Copaxone 810 10,71%

5 (6) L01X 2686 13,89% 3,32% Nexavar 433 58,95%

Glivec 877 9,66%

Sutent 516 -27,04%

Estonian pharmacy and hospital market 2012 1Q – 2013 2Q


Contacts

In case you have any questions, please contact persons provided below.

Gediminas Pukys

Analyst

UAB SoftDent

Phone +370 654 29750

Email [email protected]

Jolita Kazlauskienė

Sales Manager

UAB SoftDent

Phone +370 685 81266

Email [email protected]

Thank you in advance for your feedback, comments or suggestions.

www.softdent.lt ; +370 37 424 734; 37 425 428 20

mailto:[email protected]

mailto:[email protected]

http://www.softdent.lt/

BALTIC STATES PHARMA MARKET OVERVIEW · •Introduction •General overview • Sales dynamics in...

Documents

Transcript of BALTIC STATES PHARMA MARKET OVERVIEW · •Introduction •General overview • Sales dynamics in...